ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act By Ogkologos - June 11, 2025 801 0 Facebook Twitter Google+ Pinterest WhatsApp Ensuring equitable access to cancer treatments remains central to EU health security efforts Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Efficacy Outcomes of Olaparib in Patients with mCRPC with BRCA Alterations... November 21, 2023 No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in... September 26, 2024 EMA Recommends Granting a Marketing Authorisation for Fruquintinib May 13, 2024 Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults February 25, 2019 Load more HOT NEWS Adding Sintilimab to Chemoradiotherapy Improves Event-Free Survival in Patients with High-Risk... Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening... Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates...
